July 17, 2018 04:29 PM EDT
Financing
China

Pre-rev­enue vac­cine de­vel­op­er CanSi­no lines up at a buzzing HKEX

Amber Tong

On the same day As­cle­tis start­ed pub­licly pitch­ing its his­toric IPO on the Hong Kong stock ex­change, an­oth­er home­grown drug­mak­er is tak­ing its own …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Lil­ly’s oral SERD makes strides in breast can­cer with Phase 3 da­ta

The End­points 100: The biotech in­dus­try braces for Trump 2.0

Ex­clu­sive: Bain-backed mus­cu­loskele­tal biotech rais­es $120M for trio of clin­i­cal-stage bi­o­log­ics

Ace­lyrin says good­bye to the drug that got it a $540M IPO in 2023

Chro­ma, Nvel­op merge to form nChro­ma Bio, rais­ing $75M to en­ter the clin­ic

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times